Epicardial Fat, Visceral Fat and Coronary Atherosclerosis
Study Details
Study Description
Brief Summary
Background: Visceral fat is increasingly associated with metabolic syndrome and with fatty liver, a condition carrying a high risk of cardiovascular disease. The independent role of epicardial fat deposition in cardiovascular risk remains unclear.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Detailed Description
Background: Visceral fat is increasingly associated with metabolic syndrome and with fatty liver, a condition carrying a high risk of cardiovascular disease. The independent role of epicardial fat deposition in cardiovascular risk remains unclear. Aim: Evaluate the link between epicardial fat, visceral fat, liver fat accumulation and cardiovascular diseases and carotis atherosclerosis in patients with the major cardiovascular risk factors and with or without metabolic syndrome.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
patient with liver fat 30 patients with liver fat |
Other: patient with liver fat
30 patient with liver fat
|
excess of visceral fat 50 pts. with excess of visceral fat |
Other: pts. with excess of visceral fat
pts. with excess of visceral fat
|
control 30 control subjects |
Other: control
30 control subjects
|
Outcome Measures
Primary Outcome Measures
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients referred to cardiac CT will be the source of recruitment.
-
patients with excess of visceral fat,
-
30 patients with liver fat accumulation
-
30 sex-age-matched individual (controls) will be enrolled. All patients will undergo a complete family history, personal clinical history, physical examination and blood sampling for biochemical analysis.
-
Informed consent will be obtained from each individual.
Exclusion Criteria:
-
subjects with severe morbid obesity (body mass index [BMI] > 40),
-
recent history of acute illness,
-
clinical history of ischemic heart disease and cerebrovascular disease,
-
typical chest pain,
-
previous coronary artery disease,
-
conventional coronary angiography, percutaneous interventions, coronary by pass grafting, renal failure, cancer patients,
-
subjects who take drugs that induces hepatic steatosis ( corticosteroids, estrogens, methotrexate, amiodarone and others)
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Ziv MC | Safed | Israel | 13100 |
Sponsors and Collaborators
- Ziv Hospital
Investigators
- Principal Investigator: Nimer Assy, md, Ziv MC
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 0020-11